Vistagen updates fasedienol Phase 3 timelines: PALISADE-3 data Q4 2025, PALISADE-4 H1 2026

Vistagen Therapeutics, Inc.

PALISADE-3 topline data remains on track for Q4 2025; PALISADE-4 now expected in H1 2026.
Positive PALISADE-2 results (2023) plus success in either PALISADE-3 or -4 could support NDA submission.
Protocol enhancements include site training, surveillance, and subject selection to replicate PALISADE-2 success.
CEO cites strong patient/physician enthusiasm and growing unmet need in social anxiety disorder.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.